Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Myung S Kim

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Journal of Cancer Research and Clinical Oncology|October 22, 2022
Pembrolizumab for allMyung S Kim, Vinay Prasad
JAMA Internal Medicine|February 22, 2021
Approval and Coverage of Cancer Drugs in England, Canada, and the USVinay Prasad, Myung S Kim
JAMA Internal Medicine|October 29, 2019
The Clinical Trials Portfolio for On-label and Off-label Studies of EculizumabMyung S Kim, Vinay Prasad
European Journal of Cancer (Oxford, England : 1990)|July 3, 2021
New drugs and options can enhance patient outcomes: But can they also erode them?Myung S Kim, Vinay Prasad
BMJ Evidence-Based Medicine|June 4, 2021
When we move cancer drugs from the second or third to the first line of treatment: what lessons can we learn from KEYNOTE-177 and JAVELIN-100Myung S Kim, Vinay Prasad
European Journal of Cancer (Oxford, England : 1990)|August 13, 2021
Nested and adjacent subgroups in cancer clinical trials: When the best interests of companies and patients divergeMyung S Kim, Vinay Prasad
Cleveland Clinic Journal of Medicine|March 9, 2019
Cancer screening: A modest proposal for preventionMyung S Kim, Go Nishikawa, Vinay Prasad
Blood|November 25, 2020
Persistent challenges with treating multiple myeloma earlyAaron M Goodman, Myung S Kim, Vinay Prasad
JAMA Oncology|April 14, 2022
Addressing Sex Disparities in Academic Oncology: What Can We Do?Kristina Jenei, Malinda T West, Myung S Kim
International Journal of Cancer|February 19, 2022
Quality of biomarker defined subgroups in FDA approvals of PD-1/PD-L1 inhibitors 2014 to 2020Myung S Kim, Alexander Xu, Alyson Haslam, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Journal of Cancer Research and Clinical Oncology|October 22, 2022
Pembrolizumab for allMyung S Kim, Vinay Prasad
JAMA Internal Medicine|February 22, 2021
Approval and Coverage of Cancer Drugs in England, Canada, and the USVinay Prasad, Myung S Kim
JAMA Internal Medicine|October 29, 2019
The Clinical Trials Portfolio for On-label and Off-label Studies of EculizumabMyung S Kim, Vinay Prasad
European Journal of Cancer (Oxford, England : 1990)|July 3, 2021
New drugs and options can enhance patient outcomes: But can they also erode them?Myung S Kim, Vinay Prasad
BMJ Evidence-Based Medicine|June 4, 2021
When we move cancer drugs from the second or third to the first line of treatment: what lessons can we learn from KEYNOTE-177 and JAVELIN-100Myung S Kim, Vinay Prasad
European Journal of Cancer (Oxford, England : 1990)|August 13, 2021
Nested and adjacent subgroups in cancer clinical trials: When the best interests of companies and patients divergeMyung S Kim, Vinay Prasad
Cleveland Clinic Journal of Medicine|March 9, 2019
Cancer screening: A modest proposal for preventionMyung S Kim, Go Nishikawa, Vinay Prasad
Blood|November 25, 2020
Persistent challenges with treating multiple myeloma earlyAaron M Goodman, Myung S Kim, Vinay Prasad
JAMA Oncology|April 14, 2022
Addressing Sex Disparities in Academic Oncology: What Can We Do?Kristina Jenei, Malinda T West, Myung S Kim
International Journal of Cancer|February 19, 2022
Quality of biomarker defined subgroups in FDA approvals of PD-1/PD-L1 inhibitors 2014 to 2020Myung S Kim, Alexander Xu, Alyson Haslam, et al.
Pageof 2